Presentation is loading. Please wait.

Presentation is loading. Please wait.

TITLE lecturer Institution. Presenter Disclosure Information.

Published byIsabel Hardy Modified over 8 years ago

Similar presentations

Presentation on theme: "TITLE lecturer Institution. Presenter Disclosure Information."— Presentation transcript:

1 TITLE lecturer Institution

2 Presenter Disclosure Information

3 CASE SUMMARY Patient demographics Age Gender Risk factors Past medical history Clinical presentation Sympotam CCS class Cardiac markers Echo Renal function

4 BASELINE ANGIOGRAPHY

5

6  Euro score  SYNTAX score  NERS score  。。。。 RISK STRATIFICATION

7 STRATEGY Reason/guidelinePossible problem/choice

8 STEP 1 Instrument/device

9 STEP 2 Instrument/device

10 STEP 3 Instrument/device

11 FINAL ANGIOGRAPHY

12 POST PROCEDURE Sympotam CCS class Cardiac markers Echo Renal function

13 FOLLOW-UP ANGIOGRAPHY

14 Summarize ／ Take Home Message

15 Thanks for Your Attention ！

Download ppt "TITLE lecturer Institution. Presenter Disclosure Information."

Similar presentations

When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.

When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.
ACME Marketing Plan Presented by Sydney Division [Slide 1]

ACME Marketing Plan Presented by Sydney Division [Slide 1]
In austere financial times, which procedures should be rationed and who should decide? Jason Yuen Final year medical student – University of Oxford Professor.

In austere financial times, which procedures should be rationed and who should decide? Jason Yuen Final year medical student – University of Oxford Professor.
Patient Demographics: AGE: 67 year old Gender: Female Cardiac risk Factors: Hypertension, Diabetes, hypercholesterolemia Clinical Presentation: NSTEMI.

Patient Demographics: AGE: 67 year old Gender: Female Cardiac risk Factors: Hypertension, Diabetes, hypercholesterolemia Clinical Presentation: NSTEMI.
5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.

5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.
V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.

V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.
Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.

Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.
A multicenter, randomized, prospective DKCRUSH-III study

A multicenter, randomized, prospective DKCRUSH-III study
AKI Definitions Stuart L. Goldstein, MD Professor of Pediatrics University of Cincinnati College of Medicine Director, Center for Acute Care Nephrology.

AKI Definitions Stuart L. Goldstein, MD Professor of Pediatrics University of Cincinnati College of Medicine Director, Center for Acute Care Nephrology.
CCE 4: Bridging Clinical Expertise Using Predictive Computational Cancer Models CRC screening and follow-up – Semi-mechanistic model of CRC development.

CCE 4: Bridging Clinical Expertise Using Predictive Computational Cancer Models CRC screening and follow-up – Semi-mechanistic model of CRC development.
Complication after Procedure Resident Name, MD Attending Name, MD Institution Morbidity & Mortality Conference Date.

Complication after Procedure Resident Name, MD Attending Name, MD Institution Morbidity & Mortality Conference Date.
Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.

Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.
Ischaemic Heart Disease for the GP Chris Tracey GPVTS.

Ischaemic Heart Disease for the GP Chris Tracey GPVTS.
Poster Title Author(s) Institution Poster Title Author(s) Institution INTRODUCTION HISTORY SIMSCON 2015 1 8 th South Indian Medical Students’ Conference,

Poster Title Author(s) Institution Poster Title Author(s) Institution INTRODUCTION HISTORY SIMSCON th South Indian Medical Students’ Conference,
Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.

Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.
Findings suggest: -Although the participants reported high medication compliance at baseline, improvement was noted. -The improvement in medication adherence.

Findings suggest: -Although the participants reported high medication compliance at baseline, improvement was noted. -The improvement in medication adherence.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.

Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
Fabiani & Budhrani Heart Institute Commissioned on June 4, 2006.

Fabiani & Budhrani Heart Institute Commissioned on June 4, 2006.
Will my Glaucoma patient lose vision ?

Will my Glaucoma patient lose vision ?
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.

Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.

Similar presentations

Ads by Google